Keynote review: Histamine H3 receptor antagonists reach out for the clinic
- 22 December 2005
- journal article
- review article
- Published by Elsevier BV in Drug Discovery Today
- Vol. 10 (23-24), 1613-1627
- https://doi.org/10.1016/s1359-6446(05)03625-1
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- Effect of combined histamine H1 and H3 receptor blockade on cutaneous microvascular permeability elicited by compound 48/80Life Sciences, 2005
- Assessment of pharmacology and potential anti-obesity properties of H3receptor antagonists/inverse agonistsExpert Opinion on Investigational Drugs, 2005
- Acute wake‐promoting actions of JNJ‐5207852, a novel, diamine‐based H3 antagonistBritish Journal of Pharmacology, 2004
- Perspectives on cognitive domains, H3receptor ligands and neurological diseaseExpert Opinion on Investigational Drugs, 2004
- The role of histamine and the tuberomamillary nucleus in the nervous systemNature Reviews Neuroscience, 2003
- Structure–activity relationships of non-imidazole H3 receptor ligands. Part 1Bioorganic & Medicinal Chemistry Letters, 2002
- Inhibition and Induction of Cytochrome P450 and the Clinical ImplicationsClinical Pharmacokinetics, 1998
- Effects of clobenpropit (VUF-9153), a histamine H3-receptor antagonist, on learning and memory, and on cholinergic and monoaminergic systems in miceLife Sciences, 1997
- Involvement of histamine in the control of the waking stateLife Sciences, 1993
- Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptorNature, 1983